Whalesbook
India's Diplomatic Push on Intellectual Property
Indian industry confederations have formally requested the Office of the United States Trade Representative (USTR) to delist India from its Priority Watch List. This move is underpinned by claims of sustained reform measures, demonstrable progress, and enhanced strategic cooperation aimed at addressing intellectual property (IP) protection concerns raised by U.S. industries. The appeals gain significance against the backdrop of recent high-level discussions signaling a potential interim agreement on reciprocal trade between the two nations. The USTR's Priority Watch List, a component of the annual Special 301 Report, categorizes countries based on their IP protection and enforcement frameworks, with placement indicating areas of concern for U.S. businesses.
Trade and Investment Implications
India's position on the USTR's Priority Watch List has historically signaled potential trade friction, a factor the Indian Pharmaceutical Alliance (IPA) and the Confederation of Indian Industry (CII) argue no longer accurately reflects the nation's evolving IP regime. Despite strong bilateral trade, which totaled an estimated $212.3 billion in 2024, and recent progress toward a trade framework, persistent IP concerns remain a point of contention. The U.S. maintains a significant goods trade deficit with India, which widened by 5.9% to $45.8 billion in 2024. For India, its pharmaceutical sector, a major export contributor with $30.4 billion in exports in FY 2024-25, faces scrutiny. The U.S. is a key destination, accounting for approximately 34% of India's pharmaceutical exports. Removal from the Priority Watch List could be viewed as a favorable signal, potentially smoothing trade relations and encouraging further foreign investment, especially as a new interim trade agreement framework is being discussed that includes IP protection.
The Analytical Deep Dive
While industry bodies advocate for India's removal, the broader IP landscape presents a mixed picture. India has seen remarkable growth in IP filings, ranking sixth globally in patent applications and fourth in trademark filings by volume in 2023, demonstrating a strong upward trajectory in innovation activity. The World Intellectual Property Organization (WIPO) 2024 report highlights India's fastest growth in patent applications among the top 20 origins. However, the U.S. Chamber of Commerce's International IP Index, a key benchmark, ranked India 42nd out of 55 countries in 2022, with noted room for improvement in patent protection and enforcement. The USTR's 2025 Special 301 Report continues to identify India as one of the world's most challenging major economies for IP protection and enforcement, despite acknowledging some progress. The Indian pharmaceutical sector, while a global leader in generic medicines and vaccine production, invests variably in R&D, with companies reporting spending between 5.8% and 11% of revenue, which remains lower than that of leading innovation economies.
The Forensic Bear Case
The USTR's persistent concerns, reflected in annual Special 301 Reports, paint a cautious outlook. Key issues include the potential threat of patent revocations, procedural and discretionary invocation of patentability criteria under the Indian Patents Act, high customs duties on IP-intensive products, and weak IP enforcement by law enforcement agencies. Reports frequently cite issues such as online piracy, trademark opposition backlogs, and insufficient legal recourse for trade secrets. For instance, the 2025 report indicated a lack of progress on many long-standing concerns, despite India's efforts to strengthen its IP regime and increased engagement with the U.S.. Unlike some competitors, India's R&D spending as a percentage of GDP is notably lower than in countries like South Korea or the United States. Furthermore, patent grants to non-resident entities have often surpassed those to domestic applicants, raising questions about the domestic innovation ecosystem's full benefit from the IP framework. The lack of specific civil or criminal laws addressing trade secret protection remains a significant gap.
Future Outlook
The ongoing trade negotiations between India and the U.S., including the framework for an interim agreement, are expected to address these IP-related concerns directly. The USTR's decision on India's watchlist status will likely hinge on the perceived effectiveness and implementation of recent reform efforts, such as the Patents (Amendment) Rules, 2024. While Indian industry groups push for de-listing, signaling a desire for a more predictable trade and investment environment, the USTR's annual assessment will continue to scrutinize the tangible progress in IP protection and enforcement. Any significant move on the Priority Watch List could offer a tailwind for sectors like pharmaceuticals and technology, potentially easing market access and boosting investor confidence.